What Makes Medpace Holdings (MEDP) an Investment Choice?

Group 1 - Giverny Capital Asset Management reported a third-quarter 2025 return of 6.78%, underperforming the S&P 500 which returned 8.12% [1] - Year-to-date, the fund's return is 12.57%, compared to 14.83% for the S&P 500 index [1] - The fund's top 5 holdings were highlighted as key investment picks for 2025 [1] Group 2 - Medpace Holdings, Inc. (NASDAQ:MEDP) is identified as a significant investment, with a one-month return of -8.89% and a 52-week gain of 60.60% [2] - As of December 08, 2025, Medpace's stock closed at $549.17 per share, with a market capitalization of $15.47 billion [2] - The company specializes in clinical research and provides services for early-stage biopharmaceutical companies conducting clinical trials [3] Group 3 - Giverny Capital Asset Management acquired shares in Medpace Holdings, Inc. at approximately $381 last year, indicating confidence in the company's growth potential [3] - The investment decision was supported by insights from partners in Montreal who had a deep understanding of Medpace [3] - The company plays a crucial role in helping start-ups with promising drug compounds conduct trials to demonstrate efficacy [3]